Compare TTWO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | TAK |
|---|---|---|
| Founded | 1993 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1B | 43.3B |
| IPO Year | 1997 | N/A |
| Metric | TTWO | TAK |
|---|---|---|
| Price | $247.21 | $16.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $273.47 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 2.8M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $6,219,900,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $17.38 | N/A |
| Revenue Next Year | $37.08 | $0.47 |
| P/E Ratio | ★ N/A | $121.37 |
| Revenue Growth | ★ 13.98 | N/A |
| 52 Week Low | $181.86 | $12.99 |
| 52 Week High | $264.79 | $16.93 |
| Indicator | TTWO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 66.14 |
| Support Level | $242.73 | $15.78 |
| Resistance Level | $257.91 | $16.93 |
| Average True Range (ATR) | 5.41 | 0.23 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 55.57 | 77.83 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.